Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now
Rafael Fonseca MD
Rafael Fonseca MD Editor-in-Chief
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
See All Experts
featured
Published in Oncology and
2 other channels

Expert Opinion / Interview · June 08, 2017

The New Standard of Care? Abiraterone in Metastatic Prostate Cancer

Farzanna Haffizulla MD, FACP, FAMWA
Oliver Sartor MD
Interview with
Oliver Sartor MD

 

 Save  Recommend
 Share

Additional Info

  1. James ND, De Bono JS, Spears MR, et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476). Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA5003.
  2. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-746.
  3. Fizazi K, Tran N, Fein LE, et al LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA3.

Disclosure statements are available on the authors' profiles:

Oliver Sartor MD

Further Reading

Most Read This Week

Recently Updated